Journal Article

Cefepime Therapy and All-Cause Mortality

Thao D. Nguyen, Byron Williams and Elizabeth Trang

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 48, issue 7, pages 902-904
Published in print April 2009 | ISSN: 1058-4838
Published online April 2009 | e-ISSN: 1537-6591 | DOI:
Cefepime Therapy and All-Cause Mortality

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology


Show Summary Details


The findings of increased all-cause mortality associated with cefepime therapy reported in a 2007 meta-analysis by Yahav and colleagues in The Lancet Infectious Disease prompted an early communication by the Food Drug Administration (FDA). The FDA stated that it would review more safety data to further evaluate the risk of death to patients treated with cefepime. The meta-analysis' conclusion and the FDA early communication have stirred up debates in many institutions about how to properly adjust their antibiotic practice. Our review of the method of the meta-analyis (e.g., the method of data collection) raises questions about its conclusion; we call for additional review of the clinical data before any effort is made to limit or eliminate cefepime from the current practice guidelines. We make a number of recommendations on the appropriate use of cefepime therapy while awaiting further FDA advice.

Journal Article.  2230 words. 

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.